| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,820,000 |
| Market
Cap: |
126.73(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.62 - $4.13 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Poseida Therapeutics is a clinical-stage biopharmaceutical company. Co.'s chimeric antigen receptor T cell (CAR-T) product candidate includes P-BCMA-101, which is an autologous CAR-T being developed for the treatment of patients with metastatic castrate resistant prostate cancer. Co.'s dual CAR-T allogeneic program candidates include P-CD19CD20-ALLO1, which is an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications and some autoimmune disease. Co.'s gene therapy programs include P-OTC-101, which is an in vivo liver-directed gene therapy candidate for the treatment of ornithine transcarbamylase deficiency.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,292,857 |
| Total Buy Value |
$0 |
$0 |
$0 |
$8,025,000 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
160,696 |
| Total Sell Value |
$0 |
$0 |
$0 |
$592,808 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rizvi Syed Ali-Aamir |
Chief Medical Officer |
• – – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
185,000 |
185,000 |
|
- |
|
| Gergen Mark J |
Executive Chairman |
• • – |
2024-03-01 |
4 |
D |
$4.13 |
$141,068 |
D/D |
(34,157) |
651,291 |
|
- |
|
| Leonhardt Harry J |
GC & Chief Compliance Officer |
• – – |
2024-03-01 |
4 |
D |
$4.13 |
$67,344 |
D/D |
(16,306) |
214,640 |
|
- |
|
| Leonhardt Harry J |
GC & Chief Compliance Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
80,743 |
230,946 |
|
- |
|
| Warner Brent |
President, Gene Therapy |
• – – |
2024-03-01 |
4 |
D |
$4.13 |
$147,602 |
D/D |
(35,739) |
419,040 |
|
- |
|
| Warner Brent |
President, Gene Therapy |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
80,743 |
454,779 |
|
- |
|
| Mylet Johanna |
Chief Financial Officer |
• – – |
2024-03-01 |
4 |
D |
$4.13 |
$74,716 |
D/D |
(18,091) |
246,283 |
|
- |
|
| Mylet Johanna |
Chief Financial Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
80,743 |
264,374 |
|
- |
|
| Gergen Mark J |
Executive Chairman |
• • – |
2024-02-01 |
4 |
D |
$3.41 |
$160,822 |
D/D |
(47,162) |
685,448 |
|
- |
|
| Yarema Kristin |
President and CEO |
• • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
606,836 |
|
- |
|
| Gergen Mark J |
Executive Chairman |
• • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
732,610 |
|
- |
|
| Corning Luke |
|
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
39,300 |
|
- |
|
| Schmid John P. |
|
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
39,300 |
|
- |
|
| Baum Charles M |
|
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
58,950 |
|
- |
|
| Collins Cynthia |
|
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
39,300 |
|
- |
|
| Lloyd Marcea Bland |
|
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
49,300 |
|
- |
|
| Amado Rafael |
Director |
– • – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
39,300 |
39,300 |
|
- |
|
| Yarema Kristin |
President, Cell Therapy |
• – – |
2023-04-11 |
4 |
A |
$0.00 |
$0 |
D/D |
356,836 |
356,836 |
|
- |
|
| Mylet Johanna |
Chief Financial Officer |
• – – |
2023-03-01 |
4 |
D |
$5.35 |
$23,128 |
D/D |
(4,323) |
177,631 |
|
- |
|
| Mylet Johanna |
Chief Financial Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
92,772 |
181,954 |
|
- |
|
| Leonhardt Harry J |
GC & Chief Compliance Officer |
• – – |
2023-03-01 |
4 |
D |
$5.35 |
$23,128 |
D/D |
(4,323) |
144,203 |
|
- |
|
| Leonhardt Harry J |
GC & Chief Compliance Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
92,772 |
148,526 |
|
- |
|
| Warner Brent |
President, Gene Therapy |
• – – |
2023-03-01 |
4 |
D |
$5.35 |
$142,401 |
D/D |
(26,617) |
374,036 |
|
- |
|
| Warner Brent |
President, Gene Therapy |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
92,772 |
400,653 |
|
- |
|
| Gergen Mark J |
President and CEO |
• • – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
269,586 |
601,610 |
|
- |
|
103 Records found
|
|
Page 1 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.02 (0.97%) 
